FDA Alert: Abiomed Impella Blood Pump Urgent Recall
Controller may fail to detect the Impella deviceAbiomed Impella blood pump controllers
Controller May Fail to Detect Device
Abiomed has issued an urgent safety notice for its Automated Impella Controller (AIC) due to a potentially serious issue where the system may fail to detect the Impella blood pump when connected.
This malfunction could result in inadequate cardiac support, which is especially dangerous for patients in cardiogenic shock.
Affected Products, Product Codes, UDI-DIs, and Serial Numbers (click on the link to download a list.)
Key Details
- Issue: The controller may not recognize the connected pump during startup or transfer between consoles.
- No visual alarm appears on screen to indicate a problem.
- Reported Cases: 3 patient deaths have been linked to this issue as of June 13; no serious injuries reported.
- Impacted Devices: All AICs across the Abiomed Impella pump line.
Recommended Actions
- Always have a backup AIC available.
- If the pump isn’t detected within 20 seconds:
- Switch back to the previous console.
- Reboot the non-responsive console.
- Start the case on a different AIC if needed.
- Distribute this alert to all relevant clinical staff and facilities.
- Forward notice to any facility that received affected products.
Why It Matters
Failure to detect the pump could lead to delayed or absent hemodynamic support, putting critically ill patients at high risk.
For questions or to report adverse events, contact Abiomed at (978) 646-1400.
The FDA is actively reviewing this high-risk issue and will provide updates here as more information becomes available.
Read more about Mechanical Circulatory Support (MCS) devices
A Team-based Approach to an Expedited 510(k)
Getting an expedited 510(k) submission So, you have created a new medical device by following your quality system’s design controls to plan the project, define design inputs, test to verify that outputs meet inputs, and validated your production product. Now what?...
FDA Warning Letter to Olympus Medical Systems
Letter addresses several violations of FDA&C Act On March 15, 2023, the Food and Drug Administration (FDA) issued a Warning Letter to Olympus Medical Systems Corp. The letter addressed several violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act)...
Class I Recall for Intra-Aortic Blood Pumps
Datascope/Getinge IABPs May Malfunction Due to Cable Failure The US Food and Drug Administration (FDA) announced yesterday that Datascope/Getinge is recalling certain CARDIOSAVE Hybrid and Rescue Intra-Aortic Balloon Pumps (IABP) due to a risk of device malfunction....